Markets:

Overview

News

Currencies

International

Treasuries

GH Research PLC - Ordinary Shares (NQ:GHRS)

28.82 -0.10 (-0.35%)

Streaming Delayed Price Updated: 2:01 PM EDT, Aug 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about GH Research PLC - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

Psyched: Steve Cohen's New Biopharma Bet, California Gov. Authorizes Medical Psychedelics & More ↗

October 06, 2023

Steve Cohen Keeps Betting On Biopharma With Purchase Of 119M+ Bionomics Shares

Via Benzinga

Major Psychedelic Drug Stocks Continued To Decline This Week ↗

October 06, 2023

A review of the performances of the 5 stocks in the Psychedelic Drug Stocks Index this week and since the end of August along with links to their latest news.

Via Talk Markets

GH Research's Psychedelic Drug Candidate For Depression Meets FDA: Clinical Program On Hold ↗

October 02, 2023

After the usual 30-day review period, the Food and Drug Administration (FDA) placed GH Research’s (NASDAQ: GHRS) Investigational New Drug (IND) application for a Phase 1 clinical trial of proprietary...

Via Benzinga

Psyched: DMT & SSRIs For Depression, MDMA Training, Negative Responses To Psychedelics & More ↗

October 02, 2023

Depression Relief: Possible Therapy Boost With DMT & SSRIs Small Pharma Clinical Results New findings on safety, tolerability and efficacy from a clinical study assessing the interaction of...

Via Benzinga

September Summary: Largest Psychedelic Drug Stocks Dropped 14% ↗

October 01, 2023

Seelos Therapeutics' market capitalization dropped below $50M with the recent dramatic decline in its share price and, as such, is no longer part of the Psychedelic Drug Stocks Index. The remaining...

Via Talk Markets

GH Research Provides Updates and Guidance on its Clinical Development Program for GH001 in Treatment-Resistant Depression

September 29, 2023

From GH Research PLC

Via GlobeNewswire

Psyched: Steve Cohen Goes Big On Cybin, Fed Intervention On Psilocybin, Ketamine Insurance And More ↗

September 26, 2023

Billionaire Steve Cohen Buys 19M Shares Of Cybin Stock For Psychedelics R&D, Blake Mycoskie $100M Pledge

Via Benzinga

Topics Economy

Psychedelic Drug Stocks Dragged Down By 83% Collapse In SEEL Stock Price ↗

September 24, 2023

With the 82.6% collapse of Seelos Therapeutics (SEEL) last week, the 6 psychedelic-compound-based research & development stocks in our Psychedelic Drug Stocks Index declined by 13.0%, on average, and...

Via Talk Markets

Psyched: MDMA Trials For PTSD, Congressional Amendments, Scotland's Consumption Site & More ↗

September 18, 2023

Treating PTSD With MDMA Therapy: New Results From MAPS Clinical Study, FDA Submission Next

Via Benzinga

4 Of The 6 Largest Psychedelic Compound-Based R & D Stocks Had A Good Week ↗

September 17, 2023

4 of the 6 psychedelic-compound-based research & development stocks in our Psychedelic Drug Stocks Index were up in price last week versus only 1 the previous week. The Index was up 2.4% for the week...

Via Talk Markets

Psyched: Psilocybin Therapy For Depression, UK Rescheduling, US Policy Reform And More ↗

September 11, 2023

Single Psilocybin Dose 'Significantly' Reduces Major Depression Symptoms, An AI Predictive Model, And UK’s Struggle For Reclassification

Via Benzinga

Topics Artificial Intelligence

6 Largest Psychedelic Compound-Based R & D Stocks In Decline ↗

September 10, 2023

The 6 psychedelic compound-based research & development stocks in our Psychedelic Drug Stocks Index were down 2.6%, on average, this week and are now only up 6.5% YTD.

Via Talk Markets

6 Largest Psychedelic Compound-Based R & D Stocks Up 4%, On Average, Last Week ↗

September 05, 2023

The 6 psychedelic compound-based research & development stocks in our munKNEE Psychedelic Drug Stocks Index were UP 3.9%, on average, last week and are now only UP 9.4% YTD.

Via Talk Markets

Psyched: Three Noteworthy Psychedelics M&As, Colorado's Regulations, Exclusive Financing & More ↗

September 05, 2023

Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety

Via Benzinga

August Recap: Largest Psychedelic Compound-Based R & D Stocks Down 15% ↗

September 02, 2023

The 6 psychedelic compound-based research & development stocks in our Psychedelic Drug Stocks Index were down 15.0%, on average, in August and are now only up 5.3% YTD.

Via Talk Markets

Psyched: Psilocybin For Gambling Addiction, Ex-NHL Player's Retreat, Fellini's LSD Creativity, Surveys, Financing & More ↗

August 28, 2023

Psilocybin Therapy Trials: Gambling Addiction Study, Opioid Pain & Alcohol Addiction Trials

Via Benzinga

GH Research Psychedelics Firm Q2 2023 Reports $238M Cash To Accelerate 5-MeO-DMT Programs Into 2026 ↗

August 24, 2023

GH Research PLC (NASDAQ: GHRS), a clinical-stage biopharma company developing novel mebufotenin (5-MeO-DMT) therapies for Treatment-Resistant Depression (TRD) and one of the highest trading...

Via Benzinga

GH Research Reports Second Quarter 2023 Financial Results and Provides Business Updates

August 23, 2023

From GH Research PLC

Via GlobeNewswire

Psyched: Fed Study On Psychedelics, Janet Yellen's Magic Mushrooms, Financing Deals & Quarterly Reports ↗

August 21, 2023

Cannabis, Psychedelics Use And Binge Drinking At All-Time High Among Adults, Teens Remain Stable, Fed Study Finds

Via Benzinga

Topics Cannabis Economy

Largest Psychedelic Compound-Based R&D Stocks Continue Downward Trend ↗

August 20, 2023

The 6 psychedelic compound-based research & development stocks in our munKNEE Psychedelic Drug Stocks Index were down an average of 6% last week and are now down 17.2% MTD. We take a look at them in...

Via Talk Markets

Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More ↗

August 14, 2023

First Ever Professional Practice Guidelines For Psychedelic-Assisted Therapy Published

Via Benzinga

So Far, August Isn't Kind To 4 Of 6 Constituents In Our Psychedelic Drug Stocks Index ↗

August 13, 2023

The 6 psychedelic compound-based research & development stocks in our munKNEE Psychedelic Drug Stocks Index are down an average of 11.9% so far in August but are still up YTD.

Via Talk Markets

Psyched: Portugal Decriminalizes Synthetic Drugs, Anorexia And Psilocybin, LSD Microdosing, California & More ↗

August 03, 2023

A Revolutionary Approach: Portugal Decriminalizes Synthetic Drugs Portugal’s Parliament recently decriminalized the use of synthetic drugs. The new law equates the legal treatment of these substances...

Via Benzinga

July Summary: Largest Psychedelic Compound-Based R&D Stocks Up 16%, On Average ↗

July 30, 2023

All but 1 of the 6 largest psychedelic compound-based research & development stocks advanced in July and are ranked below as to their performances so far in July:

Via Talk Markets

Small Pharma's Q1 2024: Revamping Strategy And Potential Fast-Tracked Clinical Trial ↗

July 28, 2023

UK’s short-acting psychedelics developer Small Pharma (OTCQB: DMTTF) published its financial results for the fiscal first quarter ended May 31, 2023:

Via Benzinga

Largest Psychedelic Compound-Based Drug Stocks Up 14% MTD; Now Up 27% YTD ↗

July 23, 2023

The psychedelic compound-based drug research and development sector is UP 13.6% MTD and is now UP 26.6% YTD and this article analyzes the performance of the 6 largest stocks in the Psychedelic Drug...

Via Talk Markets

Psychedelic Compound-Based Drug Stocks Up 12% MTD; Now Up 25% YTD ↗

July 14, 2023

Our Psychedelic Drug Stocks Index is up 12.3% MTD and is now up 25.1% YTD.

Via Talk Markets

Psychedelic Stocks Jumped 10% Last Week ↗

July 09, 2023

The FDA released a positive draft guidance for developing psychedelic treatments and the 6 largest stocks in the Psychedelic Drug Stocks Index responded accordingly

Via Talk Markets

Upward Trend In Largest Psychedelic Compound-Based R&D Stocks Continues ↗

July 01, 2023

Our Psychedelic Drug Stocks Index, which consists of the 6 largest psychedelic compound-based research & development companies, was up 3.4% this week, up 7.1% in June, up 6.3% in May, and is now up...

Via Talk Markets

The 3 Best Psychedelic Stocks to Buy Now ↗

June 29, 2023

Psychedelic stocks promise to bring therapeutics to market that were taboo until recently and have huge upside.

Via InvestorPlace

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Contact Us

Contact Us

GH Research PLC - Ordinary Shares (NQ:GHRS)

All News about GH Research PLC - Ordinary Shares